tbuckley/cabot-search huggingface dataset:
Validation of FLARE‐RA, a Self‐Administered Tool to Detect Recent or Current Rheumatoid Arthritis Flare
Authors: Bruno Fautrel, Jacques Morel, Jean-Marie Berthelot, Arnaud Constantin, Michel De Bandt, Philippe Gaudin, Jean-Francis Maillefert, Olivier Meyer, Thao Pham, Alain Saraux, Elisabeth Solau-Gervais, Olivier Vittecoq, Daniel Wendling, Marie-Line Erpelding, Francis Guillemin
Journal: Arthritis & Rheumatology (2016)

To validate the measurement properties and the detection performance of the FLARE-RA questionnaire in a longitudinal prospective study.To validate the FLARE-RA self-administered questionnaire, we conducted a prospective trial in rheumatoid arthritis (RA) patients to document: 1) content and construct validity by factor analysis, convergent validity by Pearson's correlation with routine assessment of patient index data (Routine Assessment of Patient Index Data 3 [RAPID-3] questionnaire), RA Impact of Disease (RAID) score, Disease Activity Score in 28 joints (DAS28), and Health Assessment Questionnaire (HAQ), 2) reliability (intraclass correlation coefficient [ICC] and Bland-Altman plot), and 3) feasibility of use. Patients were examined and questionnaires were collected at baseline and 3 months, and every week in between for RAPID-3.We recruited 138 patients from 13 centers: 81.9% women, mean age 57.4 years, mean DAS28 2.9, mean C-reactive protein level 6.2 mg/liter, 84.4% rheumatoid factor positive, 78.0% anti-citrullinated protein antibody positive, and 78.8% with erosive disease. At baseline, the mean ± SD FLARE-RA score was 2.3 ± 2.3. The content and construct validity of FLARE-RA was good. A substantial floor effect, but no ceiling effect, was observed. Principal components analysis revealed 1 domain disentangled in 2 subdomains: physical and emotional. The FLARE-RA total score was correlated with the DAS28 (r = 0.63, P < 0.001), RAID (r = 0.80, P < 0.001), RAPID-3 (r = 0.77, P < 0.001), and HAQ (r = 0.53, P < 0.001). The ICC for reliability was 0.94 (95% confidence interval 0.92-0.96).The FLARE-RA self-administered questionnaire represents a valid and valuable instrument to detect RA flare between visits to the physician.
High INDO (Indoleamine 2,3-Dioxygenase) mRNA Level in Blasts of Acute Myeloid Leukemic Patients Predicts Poor Clinical Outcome.
Authors: Martine E.D. Chamuleau, Arjan A. Van de Loosdrecht, Corine J. Hess, Jeroen J.W.M. Janssen, Adri Zevenbergen, Ruud Delwel, Peter J.M. Valk, Bob Lowenberg, Gert J. Ossenkoppele
Journal: Blood (2007)
C2-06: Integrated PET/CT versus 3T whole body MR imaging: efficacy comparison in non-small cell lung cancer staging
Authors: Kyung-Min Shin, Chin A. Yi, Kyung Soo Lee, Byung-Tae Kim, Hojoong Kim, O Jung Kwon, Myung Jin Chung, Joon Young Choi, Seonwoo Kim
Journal: Journal of Thoracic Oncology (2007)
Antimicrobial resistance of Neisseria gonorrhoeae isolates in south-west Germany, 2004 to 2015: increasing minimal inhibitory concentrations of tetracycline but no resistance to third-generation cephalosporins
Authors: Thomas Regnath, Thomas Mertes, Ralf Ignatius
Journal: Eurosurveillance (2016)

Increasing antimicrobial resistance of Neisseria gonorrhoeae , particularly to third-generation cephalosporins, has been reported in many countries. We examined the susceptibility (determined by Etest and evaluated using the breakpoints of the European Committee on Antimicrobial Susceptibility Testing) of 434 N. gonorrhoeae isolates collected from 107 female and 327 male patients in Stuttgart, south-west Germany, between 2004 and 2015. During the study period, high proportions of isolates were resistant to ciprofloxacin (70.3%), tetracycline (48.4%; increasing from 27.5% in 2004/2005 to 57.7% in 2014/2015; p = 0.0002) and penicillin (25.6%). The proportion of isolates resistant to azithromycin was low (5.5%) but tended to increase (p = 0.08). No resistance and stable minimum inhibitory concentrations were found for cefixime, ceftriaxone, and spectinomycin. High-level resistance was found for ciprofloxacin (39.6%) and tetracycline (20.0%) but not for azithromycin; 16.3% of the isolates produced betalactamase. Thus, cephalosporins can still be used for the treatment of gonorrhoea in the study area. To avoid further increasing resistance to azithromycin, its usage should be limited to patients allergic to cephalosporins, or (in combination with cephalosporins) to patients for whom no susceptibility testing could be performed or those co-infected with chlamydiae.
Abstract MP67: Transition From Cardiovascular Disease to Cancer as the Leading Cause of Death in US States, 1999-2013
Authors: Michael C Harding, Chantel D Sloan, Ray M Merrill, Tiffany M Harding, Brian J Thacker, Evan L Thacker
Journal: Circulation (2016)

Introduction: Cardiovascular disease (CVD) has been the leading cause of death in the US, and cancer the second leading cause of death, consistently since the 1940s. In recent decades, the gap has narrowed due to the steep decline in CVD mortality and relatively modest decline in cancer mortality. We hypothesized that national-level mortality data obscure state-specific transitions from CVD to cancer as the leading cause of death. Methods: We used state-specific mortality data from the US National Vital Statistics System to calculate state-specific mortality rate ratios (RRs) of CVD vs cancer for each US state annually from 1999 to 2013. Results: From 1999 to 2013 the national CVD mortality rate fell from 265.9 to 193.3 per 100,000 and the national cancer mortality rate fell from 201.6 to 185.0 per 100,000. Accordingly, the national CVD/cancer mortality RR fell from 1.32 to 1.04. However, from 1999 to 2013 many states transitioned from CVD to cancer as the leading cause of death (see Figure). In 1999 CVD was the leading cause of death in 49 states, with median state-specific CVD/cancer mortality RR of 1.29 (IQR: 1.16, 1.36). New York had the highest mortality RR of 1.57. Only in Alaska was cancer the leading cause of death in 1999, with CVD/cancer mortality RR of 0.89. In contrast, by 2013 CVD remained the leading cause of death in only 27 states, with median state-specific CVD/cancer mortality RR of 1.08 (IQR: 1.04, 1.13). New York still had the highest mortality RR of 1.23. Cancer had become the leading cause of death in 23 states by 2013, with median state-specific CVD/cancer mortality RR of 0.95 (IQR: 0.88, 0.99). Conclusion: Due to rapidly declining CVD mortality rates, the transition from CVD to cancer as the leading cause of death has already occurred in nearly half of US states. National-level data mask this reality, implying an oversimplified public health message that “CVD is the leading cause of death.” State-specific data highlight successes in CVD prevention and control and the need for further improvements in cancer prevention and control.
Cardiomyocyte-restricted endothelial nitric oxide synthase overexpression impairs right ventricular remodeling in transgenic mice exposed to chronic hypoxia
Authors: Peter Pokreisz, Pieter Vermeersch, Z Szelid, H Gillijns, Marijke Pellens, Desire Collen, K Bloch, Stefan Janssens
Journal: Circulation (2003)
Phase II study of synchronous chemoradiotherapy with capecitabine in patients with locally advanced squamous cell carcinoma of the head and neck.
Authors: A. Jegannathen, K. Mais, A. Sykes, L. Lee, B. Yap, A. Birzgalis, J. Homer, D. Ryder, N. Slevin
Journal: Journal of Clinical Oncology (2010)

5570 Background: Cisplatin may be relatively non-discriminating in its radiosensitising action. We evaluated the efficacy of concurrent oral capecitabine with accelerated hypofractionated radical radiotherapy in locally advanced squamous cell carcinoma of head and neck (SCCHN). Methods: 50 patients with stage III/IV SCCHN were enrolled. Nineteen patients received 450-550 mg/m2capecitabine twice daily, for 28days as a part of phase I study and 31 received 500 mg/m2BD. Radiotherapy prescribed dose was 5,500cGy in 20 fractions over 4 weeks. Results: Median age was 55 (range 38-76) years, 72% had stage IV disease. Median duration of follow-up was 6 years. Forty one out of 50 (82%) patients completed the full course of capecitabine and 47/50 (94%) completed the initially prescribed radiotherapy. There were no treatment related deaths. There was no grade 3/4 haematological or renal toxicity. Five patients developed drug related grade 3 or 4 acute toxicity (cardiac, skin, bowel), 47 developed grade 3 (44) or 4 (3) mucositis from chemoradiotherapy. Twenty-two (44%) patients required tube feeding for acute mucositis with one (2%) being tube dependent at 1 year. Complete response rate at 3 months was achieved in 47/50 (94%) of patients. Relapse occurred in 14/50 (28%) patients at 5 years. The loco-regional control, overall survival and cancer specific survival at 3 and 5 years were 78% and 72%, 72% and 64% and 82% and 75% respectively. Conclusions: This schedule of capecitabine for locally advanced SCCHN is well tolerated. The local control in this series compares favourably with other synchronous chemoradiotherapy reports. Chronic dysphagia and tube dependence is uncommon with this approach. Capecitabine as targeted therapy given with each fraction of radiotherapy and administered orally may have significant advantages over intravenous, 3 weekly cisplatin. No significant financial relationships to disclose.
Epigenetic Silencing of BCL2, ETS1, IL27RA and DICER1 in Low-Risk MDS Patients
Authors: Mónica del Rey, Kathleen O'Hagan, Margaret Dellett, Sara Aibar, Hilary A. A. Colyer, María Eugenia Alonso, María Diez-Campelo, Richard N. Armstrong, Daniel J. Sharpe, Norma C. Gutiérrez, Juan Luis García, Javier de las Rivas, Ken I Mills, Jesús M. Hernández-Rivas
Journal: Blood (2012)
ALK-Positive Anaplastic Large Cell Lymphoma with the Variant EEF1G-, RNF213- and Atic-ALK Fusions Is Featured By Copy Number Gain of the Rearranged ALK Gene
Authors: Iwona Wlodarska, Jo-Anne van der Krogt, Julio Finalet Ferreiro, Jacobs Kris, Geerdens Ellen, Anne Uyttebroeck, Peter Vandenberghe, Thomas Tousseyn, Jan Cools
Journal: Blood (2015)
Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas
Authors: Nicolas Mounier, Daniele Simon, Corinne Haioun, Philippe Gaulard, Christian Gisselbrecht, Issa Khouri
Journal: Journal of Clinical Oncology (2002)

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.5.1426 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11870192 Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas Nicolas MounierxNicolas MounierSearch for articles by this author , Daniele SimonxDaniele SimonSearch for articles by this author , Corinne HaiounxCorinne HaiounSearch for articles by this author , Philippe GaulardxPhilippe GaulardSearch for articles by this author , Christian GisselbrechtxChristian GisselbrechtSearch for articles by this author Issa KhourixIssa KhouriSearch for articles by this author Show More Groupe d’Etude des Lymphomes de l’Adulte, Hôpital Saint Louis AP-HP, Paris, FranceM.D. Anderson Cancer Center, Houston, TX https://doi.org/10.1200/JCO.2002.20.5.1426 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical OncologyjcoJ Clin OncolJournal of Clinical OncologyJCO0732-183X1527-7755American Society of Clinical OncologyResponse01032002In Reply:A prospective randomized study of conventional chemotherapy (CT) versus CT followed by autologous stem-cell transplantation was started at M.D. Anderson Cancer Center in 1985 for patients with poor-risk, aggressive lymphoma having a tumor score of ≥ 3.1 Patients were randomized before starting any treatment. Those randomized to the nontransplantation arm received nine courses of alternating IdSHAP (idarubicin, cytarabine, and cisplatin), MBIDCOS (idarubicin, cyclophosphamide, vincristine, bleomycin, and solumedrol) and MINE (mesna, ifosfamide, mitoxantrone, and etoposide). Patients randomized to the transplantation arm received two courses of chemotherapy (IdSHAP and MBIDCOS) and then, if they responded, they received a course of ifosfamide/etoposide for stem-cell mobilization followed by autologous stem-cell transplantation with BEAM (carmustine, etoposide, cytarabine, and melphalan). Seventeen patients with PTCL were included. An interim intent-to-treat analysis has shown that seven (70%) of 10 patients who received high-dose chemotherapy are alive versus two (28.5%) of seven patients who were randomized to the nontransplantation arm (P = .08). This is another proof of principle that high-dose chemotherapy can potentially overcome the poor prognosis associated with T-cell immunophenotype (R.E. Champlin, personal communication, October 2001).REFERENCE1. Rodriguez J, Cabanillas F, McLaughlin P, et al: A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the tumor score. Ann Oncol 3:: 711,1992-717, Crossref, Medline, Google Scholar
P2-303: Association of polymorphisms of ATM and survival in non-small cell lung cancer patients treated with platinum combination
Authors: Jeong-Seon Ryu, Jong-Eun Lee, Yeon-Kyeong Yoo, Min-Hye Yun, Se-Kyu Kim, Seung-Min Kwak, Yeoul-Hong Kim, Eun-Soo Lee
Journal: Journal of Thoracic Oncology (2007)
Skin absorption through atopic dermatitis skin: a systematic review
Authors: A.-S. Halling-Overgaard, S. Kezic, I. Jakasa, K.A. Engebretsen, H. Maibach, J.P. Thyssen
Journal: British Journal of Dermatology (2016)

Patients with atopic dermatitis (AD) have skin barrier impairment in both lesional and nonlesional skin. They are typically exposed daily to emollients and intermittently to topical anti‐inflammatory medicaments, thereby increasing the risk of developing contact allergy and systemic exposure to chemical ingredients found in these topical preparations. We systematically searched for studies that investigated skin absorption of various penetrants, including medicaments, in patients with AD, but also in animals with experimentally‐induced dermatitis. We identified 40 articles: 11 human studies examining model penetrants, 26 human studies examining AD drugs, and three animal studies. We conclude that patients with AD have almost twofold increased skin absorption compared with healthy controls. There is a need for well‐designed epidemiological and dermatopharmacokinetic studies that examine to what extent AD causes patients to be systemically exposed to chemicals compared with nonatopic dermatitis.
Human pluripotent stem cell-derived acinar/ductal organoids generate human pancreas upon orthotopic transplantation and allow disease modelling
Authors: Meike Hohwieler, Anett Illing, Patrick C Hermann, Tobias Mayer, Marianne Stockmann, Lukas Perkhofer, Tim Eiseler, Justin S Antony, Martin Müller, Susanne Renz, Chao-Chung Kuo, Qiong Lin, Matthias Sendler, Markus Breunig, Susanne M Kleiderman, André Lechel, Martin Zenker, Michael Leichsenring, Jonas Rosendahl, Martin Zenke, Bruno Sainz, Julia Mayerle, Ivan G Costa, Thomas Seufferlein, Michael Kormann, Martin Wagner, Stefan Liebau, Alexander Kleger
Journal: Gut (2016)

Objective The generation of acinar and ductal cells from human pluripotent stem cells (PSCs) is a poorly studied process, although various diseases arise from this compartment. Design We designed a straightforward approach to direct human PSCs towards pancreatic organoids resembling acinar and ductal progeny. Results Extensive phenotyping of the organoids not only shows the appropriate marker profile but also ultrastructural, global gene expression and functional hallmarks of the human pancreas in the dish. Upon orthotopic transplantation into immunodeficient mice, these organoids form normal pancreatic ducts and acinar tissue resembling fetal human pancreas without evidence of tumour formation or transformation. Finally, we implemented this unique phenotyping tool as a model to study the pancreatic facets of cystic fibrosis (CF). For the first time, we provide evidence that in vitro , but also in our xenograft transplantation assay, pancreatic commitment occurs generally unhindered in CF. Importantly, cystic fibrosis transmembrane conductance regulator (CFTR) activation in mutated pancreatic organoids not only mirrors the CF phenotype in functional assays but also at a global expression level. We also conducted a scalable proof-of-concept screen in CF pancreatic organoids using a set of CFTR correctors and activators, and established an mRNA-mediated gene therapy approach in CF organoids. Conclusions Taken together, our platform provides novel opportunities to model pancreatic disease and development, screen for disease-rescuing agents and to test therapeutic procedures.
Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality
Authors: Taulant Muka, Clare Oliver-Williams, Setor Kunutsor, Joop S. E. Laven, Bart C. J. M. Fauser, Rajiv Chowdhury, Maryam Kavousi, Oscar H. Franco
Journal: JAMA Cardiology (2016)

As many as 10% of women experience natural menopause by the age of 45 years. If confirmed, an increased risk of cardiovascular disease (CVD) and all-cause mortality associated with premature and early-onset menopause could be an important factor affecting risk of disease and mortality among middle-aged and older women.To systematically review and meta-analyze studies evaluating the effect of age at onset of menopause and duration since onset of menopause on intermediate CVD end points, CVD outcomes, and all-cause mortality.Medical databases (ie, Medline, EMBASE, and Web of Science) until March 2015.Studies (ie, observational cohort, case-control, or cross-sectional) that assessed age at onset of menopause and/or time since onset of menopause as exposures as well as risk of cardiovascular outcomes and intermediate CVD end points in perimenopausal, menopausal, or postmenopausal women.Studies were sought if they were observational cohort, case-control, or cross-sectional studies; reported on age at onset of menopause and/or time since onset of menopause as exposures; and assessed associations with risk of CVD-related outcomes, all-cause mortality, or intermediate CVD end points. Data were extracted by 2 independent reviewers using a predesigned data collection form. The inverse-variance weighted method was used to combine relative risks to produce a pooled relative risk using random-effects models to allow for between-study heterogeneity.Cardiovascular disease outcomes (ie, composite CVD, fatal and nonfatal coronary heart disease [CHD], and overall stroke and stroke mortality), CVD mortality, all-cause mortality, and intermediate CVD end points.Of the initially identified references, 32 studies were selected that included 310 329 nonoverlapping women. Outcomes were compared between women who experienced menopause younger than 45 years and women 45 years or older at onset; the relative risks (95% CIs) were 1.50 (1.28-1.76) for overall CHD, 1.11 (1.03-1.20) for fatal CHD, 1.23 (0.98-1.53) for overall stroke, 0.99 (0.92-1.07) for stroke mortality, 1.19 (1.08-1.31) for CVD mortality, and 1.12 (1.03-1.21) for all-cause mortality. Outcomes were also compared between women between 50 and 54 years at onset of menopause and women younger than 50 years at onset; there was a decreased risk of fatal CHD (relative risk, 0.87; 95% CI, 0.80-0.96) and no effect on stroke. Time since onset of menopause in relation to risk of developing intermediate cardiovascular traits or CVD outcomes was reported in 4 observational studies with inconsistent results.The findings of this review indicate a higher risk of CHD, CVD mortality, and overall mortality in women who experience premature or early-onset menopause.
The absence of multiple atypical nevi in germline CDKN2A mutations: Comment on “Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome”
Authors: Norbertus Anton Ipenburg, Nelleke A. Gruis, Wilma Bergman, Marloes Sophia van Kester
Journal: Journal of the American Academy of Dermatology (2016)
Association of Changes in Transfusion Status with Changes in Health-Related Quality of Life of Real-World Patients with MDS Across Six Months of Treatment with Azacitidine
Authors: Chris L. Pashos, David L. Grinblatt, Mikkael A. Sekeres, Rami S. Komrokji, Mohit Narang, Arlene S Swern, Thomas K. Street, Kristen A Sullivan, Gale Harding, Zeba M. Khan
Journal: Blood (2011)
Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma.
Authors: Reinhard Dummer, Caroline Robert, Marta Nyakas, Grant A. McArthur, Ragini Reiney Kudchadkar, Carlos Gomez-Roca, Ryan J. Sullivan, Keith Flaherty, Carla Murer, Daniela Michel, Zhongwen Tang, Laure A. De Parseval, Jean-Pierre Delord
Journal: Journal of Clinical Oncology (2013)

9028 Background: LGX818, a potent and selective BRAF inhibitor (BRAFi) being investigated in BRAF V600 mutant melanoma, has unique biochemical properties with a dissociation half-time &gt; 10 times longer than other BRAF inhibitors. Methods: A phase I trial of LGX818 administered orally once (qd) or twice (bid) daily in BRAF V600 tumors was initiated to define the maximum tolerated dose (MTD)/recommended phase II dose (RP2D) and to assess pharmacokinetics and clinical activity in BRAFi–naive or pretreated patients with BRAF V600 mutant advanced melanoma. Baseline assessment of biomarkers from MAPK/PI3K pathways and pharmacodynamics were also evaluated. Results: Fifty-four patients have been enrolled in the dose-escalation phase (dose levels [DLs], 50-700 mg qd [n=42] and 75-150 mg bid [n=12]). LGX818 plasma concentrations increased proportionally by dose with a mean t 1/2 of 4 hours and steady state in ≈ 15 days. The MTD/RP2D (450 mg qd) was well tolerated. Seven patients had a dose limiting toxicity (DLT): 5 at qd (1 each with hand-foot skin reaction [HFSR], foot pain, fatigue, diarrhea/rash, insomnia/asthenia) and 2 at bid (1 facial paresis/confusion, 1 musculoskeletal pain/neuralgia). All DLTs were grade 3 and reversible. The most common adverse events (≥ 20%) suspected to be treatment related were cutaneous (rash, dry skin, HFSR, pruritus, keratosis pilaris, alopecia), pain in extremity, arthralgia, and fatigue. Squamous cell carcinoma was observed in 2 patients (1 naive and 1 pretreated). As of 30 Sept 2012, the preliminary efficacy (all DLs) in patients with at least 1 postbaseline tumor assessment was 16 partial responses [PRs] (67%; 12 confirmed) out of 24 BRAFi–naive patients and 2 PRs (8.3%; 1 confirmed) among 24 BRAFi–pretreated patients. Responses were seen at all DLs from 50 to 550 mg qd. Updated safety and efficacy including time to event endpoints will be reported. Conclusions: Initial results from this study identified the MTD/RP2D as 450 mg/day and provided an early sign of promising activity in advanced melanoma. Expansion cohorts are ongoing in BRAFi–naive and BRAFi–pretreated melanoma and colorectal cancer. Clinical trial information: NCT01436656.
Serum Adiponectin Compared with ZAP-70, CD38 and Immunoglobulin Heavy-Chain Mutation Status as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia.
Authors: Stefano Molica, Gaetano Vitelli, Giovanna Cutrona, Giovanna Digiesi, Rosanna Mirabelli, Diana Giannarelli, Isabella Sperduti, Manlio Ferrarini
Journal: Blood (2006)
Time is muscle: Delay in primary PCI results in larger infarct size by delayed enhancement cardiac magnetic resonance - Results from the APEX-AMI study
Authors: Manesh R Patel, Stephen G Worthley, Amanda Stebbins, Thorsten Dill, Frank E Rademakers, Philip E Alyward, Frans Van de Werf, Christian W Hamm, Raymond J Kim
Journal: Journal of the American College of Cardiology (2007)
Therapeutic vaccination against glioblastoma multiformae using CMV gB/pp65 eVLPs formulated with GM-CSF
Authors: D.E. Anderson, C. Soare, J. Bozic, B. Ontsouka, T. Ahmed, A. Diress, M. Yorke, A.-C. Fluckiger, M. Kirchmeier
Journal: Annals of Oncology (2015)